Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Sep;54(9):1063-71.
doi: 10.1002/jcph.298. Epub 2014 Apr 8.

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

Affiliations
Clinical Trial

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations

Cecile A Delille et al. J Clin Pharmacol. 2014 Sep.

Abstract

HIV-1 protease inhibitors (PIs) exhibit different protein binding affinities and achieve variable plasma and tissue concentrations. Degree of plasma protein binding may impact central nervous system penetration. This cross-sectional study assessed cerebrospinal fluid (CSF) unbound PI concentrations, HIV-1 RNA, and neopterin levels in subjects receiving either ritonavir-boosted darunavir (DRV), 95% plasma protein bound, or atazanavir (ATV), 86% bound. Unbound PI trough concentrations were measured using rapid equilibrium dialysis and liquid chromatography/tandem mass spectrometry. Plasma and CSF HIV-1 RNA and neopterin were measured by Ampliprep/COBAS® Taqman® 2.0 assay (Roche) and enzyme-linked immunosorbent assay (ALPCO), respectively. CSF/plasma unbound drug concentration ratio was higher for ATV, 0.09 [95% confidence interval (CI) 0.06-0.12] than DRV, 0.04 (95%CI 0.03-0.06). Unbound CSF concentrations were lower than protein adjusted wild-type inhibitory concentration-50 (IC50 ) in all ATV and 1 DRV-treated subjects (P < 0.001). CSF HIV-1 RNA was detected in 2/15 ATV and 4/15 DRV subjects (P = 0.65). CSF neopterin levels were low and similar between arms. ATV relative to DRV had higher CSF/plasma unbound drug ratio. Low CSF HIV-1 RNA and neopterin suggest that both regimens resulted in CSF virologic suppression and controlled inflammation.

Keywords: HIV/AIDS; central nervous system; clinical pharmacology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relationships between plasma and cerebrospinal fluid (CSF) unbound drug concentrations for atazanavir (ATV) and darunavir (DRV). (a) ATV (blue diamonds), Spearman rank correlation coefficient r = 0.77, P < 0.01, and (b) DRV (red diamonds), Spearman rank correlation coefficient r = 0.72, P < 0.01.
Figure 2
Figure 2
Mean cerebrospinal fluid (CSF) unbound trough concentration, standardized for each drug's wild-type protein-unbound IC50 (ATV = 1.7 ng/mL and DRV = 0.4 ng/mL) between ATV (n = 13) and DRV (n = 14). Mean unbound ATV CSF concentration was less than half of the IC50—ATV CSF concentration/IC50 ratio was 0.4 (standard error 0.1). In contrast, mean DRV CSF concentration was 8 times greater than IC50—mean DRV CSF concentration/IC50 ratio was 8.0 (standard error 2.1).

Similar articles

Cited by

References

    1. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012;37(3):377–388. - PMC - PubMed
    1. Palmer S, Josefsson L, Coffin JM. HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med. 2011;270(6):550–560. - PubMed
    1. Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS. 2013;8(3):190–195. - PMC - PubMed
    1. Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol. 2010;87(4):621–626. - PMC - PubMed
    1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799. - PMC - PubMed

Publication types

MeSH terms